Novartis News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

02.12.24	PTC Inks License And Collaboration Deal With Novartis For PTC518 Huntington's Disease Program (RTTNews)
27.11.24	Novartis Kisqali Receives EU Approval For HR+/HER2- Early Breast Cancer At High Recurrence Risk (RTTNews)
18.11.24	Ratio Therapeutics, Novartis Pharma Partner To Develop Radiotherapeutic Candidate For Cancer (RTTNews)
30.10.24	Novartis' Scemblix Receives Accelerated FDA Approval For Newly Diagnosed Ph+ CML In Adults (RTTNews)
29.10.24	Novartis Lifts FY24 Outlook After Q3 Beats Market; But Stock Down (RTTNews)
29.10.24	Novartis Raises Annual Sales Outlook After Q3 Net Profit Surges (RTTNews)
28.10.24	Monte Rosa Inks License Agreement With Novartis To Advance VAV1 MGDs (RTTNews)
27.10.24	Novartis Announces Promising 12-Month Results For Fabhalta In C3 Glomerulopathy (RTTNews)
18.10.24	Novartis Announces Positive CHMP Opinion For Kisqali - Quick Facts (RTTNews)
16.09.24	Novartis: Kisqali Reduces Recurrence Risk By 28.5% In Late-stage Early Breast Cancer Trial (RTTNews)
05.09.24	Novartis Granted License For Novel Capsid Generated From Voyager's TRACER Capsid Discovery Platform (RTTNews)
28.08.24	Lindy Biosciences Inks Multi-target Licensing Agreement And Collaboration With Novartis Pharma (RTTNews)
28.08.24	Novartis Reports Positive Topline Results From Twice-yearly Leqvio In Phase III V-MONO Study (RTTNews)
26.08.24	FT: Siemens Healthineers To Buy Advanced Accelerator Applications From Novartis (RTTNews)
11.08.24	Weekly Review: ANTX Downsizes, ALDX Aces Dry Eye Disease Trial, FDA Oks 1st Epinephrine Nasal Spray (RTTNews)
08.08.24	Novartis Receives FDA Accelerated Approval For Fabhalta As First Complement Inhibitor For IgAN (RTTNews)
31.05.24	Novartis Reports Positive Results From Phase III ASC4FIRST Trial; Meets Both Primary Endpoints (RTTNews)
31.05.24	Novartis: Phase III Data On Oral Remibrutinib Shows Long-Term Efficacy & Safety In Chronic Urticaria (RTTNews)
16.05.24	Novartis Meets Offer Conditions To Buy MorphoSys In EUR 68/shr Cash Deal (RTTNews)
10.05.24	Novartis' Scemblix Gets Breakthrough Designation For Chronic CML (RTTNews)
24.04.24	FDA Approves Novartis' Lutathera For Pediatric Gastroenteropancreatic Neuroendocrine Tumors (RTTNews)
23.04.24	Novartis Q1 Profit Tops Market, Lifts FY24 View, Proposes New Chair; Stock Up (RTTNews)
23.04.24	Novartis Q1 Profit Rises, Tops Estimates; Lifts FY24 View; Proposes Giovanni Caforio As New Chair (RTTNews)
17.04.24	Novartis : Six-Year Study Reveals Benefits Of Kesimpta In Newly Diagnosed Relapsing MS Patients (RTTNews)
16.04.24	Novartis' Fabhalta Demonstrates Significant Proteinuria Reduction In IgA Nephropathy Patients (RTTNews)
11.04.24	MorphoSys Recommends Shareholders Accept Offer By Novartis - Quick Facts (RTTNews)
11.04.24	Arvinas Enters Deal With Novartis For License Of ARV-766, Sale Of AR-V7 Program; Stock Jumps (RTTNews)
08.04.24	Novartis Data Reveals Significant LDL-C Reduction With Early Addition Of Leqvio In ASCVD Patients (RTTNews)
22.03.24	Novartis: Fabhalta Gets Positive CHMP Opinion To Treat Paroxysmal Nocturnal Hemoglobinuria (RTTNews)
22.03.24	MorphoSys Receives U.S. Antitrust Approval For Acquisition By Novartis (RTTNews)
05.03.24	Novartis Shareholders Approve Board's Proposed Resolutions (RTTNews)
04.03.24	Novartis: New SMART Study Data Continues To Support Zolgensma's Clinical Benefits In SMA (RTTNews)
06.02.24	MorphoSys Agrees To Be Acquired By Novartis For EUR 2.7 Bln (RTTNews)
31.01.24	Novartis Stock Down As Q4 Core EPS Miss Estimates; Sees Growth In FY24 (RTTNews)
31.01.24	Novartis Q4 Profit Surges, Core EPS Miss View; Sees Growth In FY24; Updates Mid-term Outlook (RTTNews)
05.01.24	Novartis Gets Approval For Commercial Production Of Pluvicto At RLT Facility In Indianapolis (RTTNews)
02.01.24	Voyager Therapeutics Enters Collaboration And Capsid License Agreement With Novartis Pharma (RTTNews)
11.12.23	Novartis: Phase III Study Shows Superiority Of Iptacopan In Patients With C3 Glomerulopathy (RTTNews)
11.12.23	Novartis : Phase III Trial Results Show Sustained Efficacy & Long-term Safety Of Fabhalta In PNH (RTTNews)
11.12.23	Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH) (PR Newswire)
06.12.23	Novartis' Fabhalta Gets FDA Approval To Treat Paroxysmal Nocturnal Hemoglobinuria In Adults (RTTNews)
06.12.23	Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH (PR Newswire)
28.11.23	Novartis Recalls Sandimmune Oral Solution (RTTNews)
13.11.23	Legend Biotech Enters Global License Agreement With Novartis Pharma For Certain CAR-T Therapies (RTTNews)
10.11.23	Novartis : Phase III Studies Of Remibrutinib In Chronic Spontaneous Urticaria Meet Main Goal (RTTNews)
01.11.23	FDA Approves Novartis' Cosentyx To Treat Moderate To Severe Hidradenitis Suppurativa In Adults (RTTNews)
30.10.23	Novartis Announces Positive Results From Phase III Study Of Atrasentan In IgA Nephropathy (RTTNews)
27.10.23	Novartis: Pluvicto Supply Now Unconstrained; FDA Classifies Drug Shortage Status As Resolved (RTTNews)
24.10.23	Novartis Q3 Profit Climbs; Lifts FY23 Core Profit View, Backs Sales Forecast (RTTNews)
23.10.23	Novartis : Pluvicto Shows RPFS Benefit In Positive Metastatic Castration-resistant Prostate Cancer (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

12.07.24		Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an
12.03.24		MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis
31.01.24		Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung
12.06.23		Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch
25.04.23		Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an
07.12.22		MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert
19.07.22		Novartis-Aktie höher: Novartis bei nahezu stabilen Umsätzen mit Gewinnrückgang - Umbau soll 1,5 Milliarden US-Dollar Kosten sparen
06.05.22		Novartis-Aktie im Minus: Produktion von Krebsmitteln in Italien und USA ausgesetzt

12.07.24

Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an

12.03.24

MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis

31.01.24

Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung

12.06.23

Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch

25.04.23

Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an

07.12.22

MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert